- 4009 Hackney Springs Ln, Sachse, TX 75048
Here’s a question worth asking first. Does Florida have one specific law called the ‘anti-markup law’? No, it doesn’t.
The Florida Anti-Markup Law refers to a group of statutes that work together. These laws stop physicians and pathology groups from charging a patient or payer more than the actual cost of a lab or pathology service performed by someone else.
Florida regulators pull this protection from clinical laboratory licensing rules, kickback statutes, and physician self-referral limits. Pathology groups that rely on outside reference labs, or that route work through referral laboratory arrangements, need to understand each piece separately. A single missed disclosure or a poorly worded fee agreement can trigger administrative fines, license discipline, or a criminal referral.
So, let’s discover the best practices to prevent these issues and understand how laboratory billing services in Florida help you stay compliant.
The Florida Statute § 483.181 governs how a clinical laboratory accepts specimens and reports results. It states that lab results must be reported directly to the licensed practitioner or other authorized person who requested it.
The statute also requires that a licensed clinical laboratory make its services available to practitioners without charging different prices based on the practitioner’s license type.
One correction is worth noting: this section doesn’t itself require printing the performing lab’s name and address on every report. That expectation comes from CLIA compliance practices for reporting and general payer disclosure requirements, not from the text of § 483.181 alone. Pathology groups should still follow that practice, since payers and patients routinely expect it, but it helps to cite the right source when training staff.
Florida Statute § 483.245 makes it unlawful for any person to pay or receive a commission, bonus, kickback, or rebate, or to enter a split-fee arrangement, connected to patients referred to a licensed clinical laboratory. It also bars a lab from leasing office space inside a physician’s practice for the purpose of setting up a specimen collection station, unless the lab and the practice share common ownership.
This is where many Florida pathology markup restrictions originate. If a lab offers a physician a discounted rate and the physician bills the difference to the patient or the payer, regulators can treat that spread as an illegal rebate.
This statute applies more broadly across health care providers, not just labs. It defines a kickback as any payment made as an incentive to refer patients, when that payment is not a legitimate, tax-deductible business expense. Violations of this section are treated as patient brokering, a serious criminal offense in Florida under § 817.505.
A reduced wholesale rate from a lab to a referring pathology group, offered in exchange for referral volume, can be read as a kickback under this statute, even without an explicit written agreement.
Every pathology group billing Medicare also answers to the Centers for Medicare & Medicaid Services (CMS). The federal anti-markup payment limitation, found at 42 CFR § 414.50, applies when a physician or supplier bills for the technical component (TC) or professional component (PC) of a diagnostic test that was performed by a physician who does not ‘share a practice’ with the billing party.
When the rule applies, Medicare payment is capped at the lowest of three figures:
It’s important to note that this federal rule does not apply to clinical diagnostic laboratory tests paid under the clinical laboratory fee schedule. Those tests follow a separate, direct-billing framework. It applies mainly to anatomic pathology and other physician-fee-schedule diagnostic services, which makes anatomic pathology billing one of the highest-risk areas for a Florida pathology group.
CMS applies a ‘substantially all services’ test, sometimes called the 75 percent rule, to decide whether a performing physician truly shares a practice with the billing physician for purposes of this exemption.
| Compliance Area | Florida State Law | Federal Rule (CMS) |
|---|---|---|
| Markup on purchased tests | Addressed indirectly through rebate and kickback statutes | Direct payment cap under 42 CFR § 414.50 |
| Disclosure of performing lab | Implied through specimen and result reporting rules | Required through CLIA and Medicare billing rules |
| Split-fee arrangements | Explicitly banned under § 483.245 | Addressed through the federal Anti-Kickback Statute |
| Self-referral limits | Broader scope under § 456.053 | Narrower scope under the federal Stark Law |
| Clinical lab test billing | Direct billing expected; no markup permitted | Excluded from § 414.50; separate fee schedule rules apply |
Most of the pathology labs run into trouble with compliance because the rules are covered in different chapters of the statutes, and no single agency publishes one master checklist.
Below are the compliance gaps we see most often, paired with a practical fix for each in the table below:
| Compliance Gap | Recommended Fix |
|---|---|
| Billing purchased tests above the referring lab's net charge | Bill strictly at acquisition cost and document the referral lab's invoice |
| Blending technical and professional component charges on one line | Separate TC and PC billing with correct modifiers, and confirm the 'shares a practice' test before combining them |
| Undisclosed referral fee agreements with outside labs | Put every referral relationship in writing and review it against § 483.245 and § 456.054 |
| Physician ownership in a referral lab without a documented exception | Confirm the arrangement meets Florida's in-office ancillary services exception under § 456.053 |
| Missing performing-lab identification on patient statements | Add the performing lab's name and CLIA number to every patient-facing statement |
Good disclosure practice protects both the patient and the practice. It’s not just paperwork. Consider these as your baseline for Florida physician billing disclosure law compliance:
The technical component covers the equipment, supplies, and staff time needed to process a specimen. The professional component covers the pathologist’s interpretation and report. Pathology technical component billing and professional component billing must be tracked and billed separately whenever different entities perform each piece. When a pathology group buys the technical work from an outside lab and bills it forward, that’s called pass-through billing.
Federal rules require billing at acquisition cost for this kind of arrangement, meaning the group can’t add a margin on top of what it paid the performing lab when the anti-markup limitation applies.
Keeping up with four overlapping state statutes and a federal payment rule is a full-time job. Many Florida independent pathology billing groups choose to outsource this work rather than build it in-house, and the reasons go beyond saving time.
A dedicated laboratory billing company in Florida brings a few advantages:
TransLabs works specifically inside this niche, supporting pathology group compliance for Florida teams with billing processes built around these exact statutes. Rather than treating compliance as a side task, outsourcing turns it into a structured and repeatable part of the revenue cycle. This lowers denial rates and protects Medicare and Medicaid participation status at the same time.